Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PHIO, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| DP CD8 TIL | HNSCC | Phase 1 · NCT05902520 | Active not recruiting |
| DP CD8 TIL KD | HNSCC | Phase 1 · NCT05902520 | Active not recruiting |
| Anti-PD-1 siRNA PH-762 | Squamous Cell Carcinoma of the Skin | Phase 1 · NCT06014086 | Completed |
Also used in these trials (approved or third-party drugs, not PHIO's own candidates): Interleukin-2.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PHIO holds $13M in cash and short-term investments (as of Jun 30, 2026) and burns about $4M/quarter from operations, an estimated runway of 9.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PHIO files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHIO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →